Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VERU Veru Inc
- Stocks
- Healthcare
- NASDAQ: VERU
Price (delayed)
$0.5156
Market cap
$75.58M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.24
Enterprise value
$58.95M
Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111,
Highlights
Veru's revenue has increased by 47% YoY
VERU's gross profit is up by 45% year-on-year
The equity has plunged by 53% YoY and by 21% from the previous quarter
The quick ratio has contracted by 15% from the previous quarter and by 9% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://verupharma.com
Key stats
What are the main financial stats of VERU
Market
Valuations
Earnings
Shares outstanding
146.58M
Market cap
$75.58M
Enterprise value
$58.95M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.59
Price to sales (P/S)
7.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.56
Revenue
$10.61M
Gross profit
$4.03M
Operating income
-$37.51M
Net income
-$36.35M
EBIT
-$35.43M
EBITDA
-$35.21M
Free cash flow
-$29.2M
Per share
Balance sheet
Liquidity
EPS
-$0.24
EPS diluted
-$0.24
Free cash flow per share
-$0.2
Book value per share
$0.14
Revenue per share
$0.07
TBVPS
$0.18
Total assets
$32.67M
Total liabilities
$11.62M
Debt
$3.39M
Equity
$21.05M
Working capital
$15.76M
Debt to equity
0.16
Current ratio
3.8
Quick ratio
3.56
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
-331.8%
Gross margin
37.9%
Net margin
-342.6%
Operating margin
-353.6%
Return on assets
-73.6%
Return on equity
-123.6%
Return on invested capital
-286%
Return on capital employed
-131%
Return on sales
-334%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VERU stock price
How has the Veru stock price performed over time
Intraday
-1.04%
1 week
2.69%
1 month
-4.99%
1 year
-61.23%
YTD
-20.74%
QTD
5.2%
Financial performance
How have Veru's revenue and profit performed over time
Revenue
$10.61M
Gross profit
$4.03M
Operating income
-$37.51M
Net income
-$36.35M
Gross margin
37.9%
Net margin
-342.6%
Veru's revenue has increased by 47% YoY
VERU's gross profit is up by 45% year-on-year
VERU's net margin is up by 37% year-on-year and by 6% since the previous quarter
The company's operating margin rose by 26% YoY
Price vs fundamentals
How does VERU's price correlate with its fundamentals
Growth
What is Veru's growth rate over time
Valuation
What is Veru stock price valuation
P/E
N/A
P/B
3.59
P/S
7.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.56
The EPS has grown by 35% YoY and by 8% from the previous quarter
The equity has plunged by 53% YoY and by 21% from the previous quarter
The P/B is 30% below the 5-year quarterly average of 5.1 but 6% above the last 4 quarters average of 3.4
Veru's revenue has increased by 47% YoY
VERU's price to sales (P/S) is 30% less than its 5-year quarterly average of 10.2 and 24% less than its last 4 quarters average of 9.4
Efficiency
How efficient is Veru business performance
The return on invested capital has dropped by 57% year-on-year and by 35% since the previous quarter
The ROS has grown by 36% YoY and by 6% from the previous quarter
The ROA has contracted by 25% YoY and by 13% from the previous quarter
Veru's ROE has decreased by 14% from the previous quarter and by 9% YoY
Dividends
What is VERU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VERU.
Financial health
How did Veru financials performed over time
The total assets is 181% more than the total liabilities
The company's total liabilities has shrunk by 56% YoY and by 12% QoQ
The total assets has plunged by 54% YoY and by 18% from the previous quarter
VERU's debt is 84% smaller than its equity
The debt to equity has soared by 60% year-on-year and by 23% since the previous quarter
The equity has plunged by 53% YoY and by 21% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.